Note 4 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at March 31, 2020
			Quoted Prices in Active		Significant Other		Significant
			Markets for		Observable		Unobservable
	Balance at		Identical Assets		Inputs		Inputs
	March 31, 2020		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	20,744	$	20,744	$	-	$	-
Total assets	$	20,744	$	20,744	$	-	$	-
Liabilities:
Contingent consideration liability	$	3,600	$	-	$	-	$	3,600
Total liabilities	$	3,600	$	-	$	-	$	3,600

			Fair Value Measurements at December 31, 2019
			Quoted Prices in Active		Significant Other		Significant
	Balance at		Markets for		Observable		Unobservable
	December 31,		Identical Assets		Inputs		Inputs
	2019		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	35,775	$	35,775	$	-	$	-
Total assets	$	35,775	$	35,775	$	-	$	-
Liabilities:
Contingent consideration liability	$	3,900	$	-	$	-	$	3,900
Total liabilities	$	3,900	$	-	$	-	$	3,900

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Program	Consideration		Form of Payment
1095		5,000	Cash or Progenics common stock
1404		9,984	Cash or Progenics common stock or cash in the case of license revenue
	$	14,984

	Consideration		Form of Payment at Progenics' Option
$30 million	$	5,000	Cash or Progenics common stock
$60 million		5,000	Cash or Progenics common stock
$100 million		10,000	Cash or Progenics common stock
$250 million		20,000	Cash or Progenics common stock
$500 million		30,000	Cash or Progenics common stock
	$	70,000

Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]

	Fair Value at
	March 31,
	2020		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
1095 commercialization	$	400	Probability adjusted discounted	Probability of success		18%
			cash flow model	Period of expected milestone achievement		2027
				Discount rate		10%
1404 commercialization		200	Probability adjusted discounted	Probability of success		43%
			cash flow model	Period of expected milestone achievement	2023	-	2035
				Discount rate		10%
Net sales targets		3,000	Monte-Carlo simulation	Probability of success	18%	-	90%
				Discount rate		10%
Total	$	3,600

	Fair Value at
	December 31,
	2019		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
1095 commercialization	$	500	Probability adjusted discounted	Probability of success		18%
			cash flow model	Period of expected milestone achievement		2026
				Discount rate		10%
1404 commercialization		300	Probability adjusted discounted	Probability of success		43%
			cash flow model	Period of expected milestone achievement	2022	-	2035
				Discount rate		10%
Net sales targets		3,100	Monte-Carlo simulation	Probability of success	18%	-	90%
				Discount rate		10%
Total	$	3,900

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Liability - Contingent Consideration
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3)
	Three Months Ended March 31,
	2020			2019
Balance at beginning of period	$	3,900		$	11,000
Fair value change included in net loss		(300	)		900
Balance at end of period	$	3,600		$	11,900
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	(300	)	$	900